Chiusura precedente | 0,3000 |
Aperto | 0,0000 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 0,3000 - 0,3000 |
Intervallo di 52 settimane | 0,2965 - 0,6355 |
Volume | |
Media Volume | 0 |
Capitalizzazione | 28,175M |
Beta (5 anni mensile) | 1,38 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,9200 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (‘APIS’), the APIS Breast Cancer Subtyping Kit and t
PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the A
PRESS RELEASE: REGULATED INFORMATION 3 October 2023, 7:00 CEST Disclosure of transparency notification Mechelen, Belgium, 3 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous p